IL17A and cancer: The analysis represented the enriched pathways in cancer affected by ALT and Brv-A include EGFR-tyrosine kinase inhibitor, PI3k-Akt signaling pathway, RAS signaling pathway, RAP1 signaling pathway, IL-17 signaling pathway, and breast cancer pathway along with EGFR tyrosine kinase inhibitor (Figure 2D).